A pharmacokinetic evaluation of the rituximab biosimilar CT-P10 in the treatment of rheumatoid arthritis.

Dae Hyun Yoo Chang-Hee SuhSeung Cheol ShimSang Joon LeeSung Hyun KimWon Park

Published in: Expert opinion on drug metabolism & toxicology (2020)

As the first biosimilar to originator RTX, CT-P10 may be a useful alternative for the treatment of RA in all indications for originator RTX. In addition, more studies are required to identify long-term effectiveness and safety of CT-P10 in real world. It is also important to find out new indications of CT-P10 and effective mechanisms to lessen nocebo effect against biosimilar including CT-P10.

Keyphrases

image quality
dual energy
computed tomography
contrast enhanced
rheumatoid arthritis
positron emission tomography
magnetic resonance imaging
disease activity
magnetic resonance
interstitial lung disease